Biotecnología
Antihemorrhagic information
Antihemorrhagic agents
Antihemorrhagic drug
Antihemorrhagic

[ Cerrar ]

thrombotarget

 

 thrombotargets

   
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
       

  
 

Procoagulant disorders


TT-103MH is the unique procoagulant drug under development able to stop bleeding caused by heparin treatment. Contact us and know more about how you can find solution for procoagulant disorders with TT-103MH. 



TT 103MH

TT-103MH is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.

Procoagulant factors

Biotechnology's innovation. Latest discover of recombinant human protein with procoagulant factors to stop bleeding, topically. The TT-103MH is being developed by Thrombotargets and will arrive at clinical phase at beginning of 2008.

Antihemorrhagic

We are developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. The most advanced drug candidate, TT-103MH, is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:


Biotech solutions
New biological drugs
BioPlatformScreen
TT-103MH
Other services
© 2006 - Thrombotargets Corp. All rights reserved - coagulation - treatment